The present disclosure generally relates to infusion devices for sequentially infusing substances into a target site. More particularly, the present disclosure relates to a co-administration assembly for sequentially infusing a plurality of substances into a target site, and an associated method.
Infusion devices are used throughout many industries to infuse a substance into a target site. One particular industry implementing infusion devices to deliver substances is veterinary medicine. For example, multiple infusion devices may be used during a so-called “dry cow program” to successively infuse substances into the udder of a cow so as to treat, control or otherwise limit the onset of bovine mastitis, i.e., the inflammation of udder tissue in cows. In such instances, a typical treatment (a so-called “dry-off procedure”) may include infusing multiple substances in succession into the teat canal of a cow, with each substance being infused using its own separate infusion device.
For example, an antimicrobial substance is first infused into the udder using a first infusion device, which is followed by a teat sealant substance being infused into the udder using a second infusion device. Between infusions, a worker must disinfect the cow teat, grab the second infusion device, and insert the second infusion device into the teat canal. Implementing two separate insertion steps into the teat canal can lead to potential issues with contamination between substance insertion if not administered properly. In this regard, the dry-off procedure is time-consuming and administratively difficult since disinfection and cleanliness are paramount.
Previous sequential delivery devices for treating bovine mastitis are single-formed devices. That is, the devices are not capable of being separated to discretely administer the antimicrobial and teat sealant substances. Such single-formed devices can present issues with regard to sterilization of the substances. In this regard, sterilization of the substances may occur after the substances have been incorporated into the devices. Sterilization of the teat sealant substance may be performed at much higher gamma radiations levels than that of the antimicrobial. In a single-formed device, such sterilization at levels necessary to sterilize the teat sealant may undesirably render the antimicrobial substance inactive.
Accordingly, it would be desirable to provide an infusion assembly capable of administering multiple substances into the cow teat following a single insertion into the teat canal, so as to lessen the chance of contamination. Such an assembly may desirably allow a worker to administer both the antimicrobial and teat sealant substances more efficiently by skipping difficult and time-consuming steps. Such an assembly may also be capable of facilitating individual use for each substance such that previous dry-off procedures could be practiced, if desired, which would also allow for individual sterilization of the substances. Furthermore, it would be desirable to provide an associated method of sequentially delivering substances into a target site using an infusion assembly.
The above and other needs are met by aspects of the present disclosure which, according to one aspect, provides an infusion assembly having a first infusion body and a first nozzle operably engaged with the first infusion body. A first plunger is configured to translate longitudinally within the first infusion body for dispensing a first substance out of the first infusion body through the first nozzle. The plunger includes a translating member and a stopper piston separable and removable from the translating member. The stopper piston is configured to facilitate a two-stage seating arrangement.
The above and other needs are met by aspects of the present disclosure which, according to one aspect, provides an infusion assembly having a first infusion body and a first nozzle operably engaged with the first infusion body. A first plunger is configured to translate longitudinally within the first infusion body for dispensing a first substance out of the first infusion body through the first nozzle. The plunger includes a translating member and a stopper piston separable and removable from the translating member.
According to some aspects, the infusion assembly has a second infusion body configured to be received within the first infusion body. A second nozzle is operably engaged with the second infusion body. A second plunger is configured to translate longitudinally within the second infusion body for dispensing a second substance out of the second infusion body through the second nozzle. The stopper piston, once separated from the translating member, is configured to receive the second nozzle such that the second plunger is capable of advancing the stopper piston to dispense the first substance from the first infusion body. The second plunger is capable of being further advanced to dispense a second substance from the second infusion body through the second nozzle and then through the first nozzle.
Another aspect provides a method of sequentially delivering a first and second substance to a target site. The method comprises providing a first infusion device having a first infusion body containing a first substance. The method further comprises providing a second infusion device having a second infusion body containing a second substance. The method further comprises positioning at least a portion of the second infusion device within the first infusion body. The second infusion device has a stopper piston removably engaged with a second nozzle thereof such that the second nozzle extends at least partially therethrough. The method further comprises advancing a plunger associated with the second infusion device such that the stopper piston interacts with the first substance so as to expel the first substance from the first infusion body through a first nozzle of the first infusion device. The method further comprises advancing the plunger so as to expel the second substance from the second infusion body through the second nozzle and then through the first nozzle to a target site.
Yet another aspect provides a kit having a first infusion device having a first substance, a second infusion device having a second substance and a nozzle, and a stopper piston configured to securely receive the nozzle. According to one aspect, the stopper piston has a penetrable portion and is compressible, wherein the stopper piston is configured to collapse such that the penetrable portion is capable of being pierced by the nozzle.
Another aspect provides a method of treatment for bovine mastitis. The method comprises inserting a nozzle of an infusion assembly into a bovine teat canal, wherein the infusion assembly is configured to successively infuse an antimicrobial substance and a teat sealant substance into the bovine teat canal. The method further comprises advancing a plunger to infuse the antimicrobial substance into the bovine teat canal. The method further comprises maintaining the nozzle of the infusion assembly within the bovine teat canal. The method further comprises advancing the plunger to infuse the teat sealant substance into the bovine teat canal.
Thus, various aspects of the present disclosure provide advantages, as otherwise detailed herein.
Having thus described various embodiments of the present disclosure in general terms, reference will now be made to the accompanying drawings, which are not necessarily drawn to scale, and wherein:
Various aspects of the present disclosure now will be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all aspects of the disclosure are shown. Indeed, this disclosure may be embodied in many different forms and should not be construed as limited to the aspects set forth herein; rather, these aspects are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout.
Accordingly, aspects of the present disclosure are provided to facilitate co-administration of substances in a sequential manner such that only one insertion event is needed to infuse multiple substances into a target site. Such aspects may be particularly advantageous in biological applications (both human and animal) where limiting insertion events at a target site is desirable. Furthermore, aspects of the present disclosure provide additional benefits in that the substances may also be individually administered such that the previously known process of separately infusing the substances may be practiced, if desired.
As shown in
According to some aspects of the present disclosure, the first plunger 130 may include a stopper piston 200 and a translating member 150. The stopper piston 200 may be separable from the translating member 150 such that the two components may be easily separated. In this regard, the stopper piston 200 may be coupled with or otherwise engaged with the translating member 150 through a snap fit. In some instances, as shown in
As shown in
The second plunger 330 may include a second guide flange member 345 capable of contacting and abutting the second flange 370 to limit advancement of the second plunger 330 within the second infusion body 310. Similarly, in some instances, the second guide flange member 345 may be configured to contact and abut the first guide flange member 145 to limit advancement of the second infusion body 310 and the stopper piston 200 within the first infusion body 110. The second plunger 330 may include a plunger head 380 having a second tip portion 360 configured to be received within the second nozzle 320 for maximizing dispense of the second substance 50 from the second infusion body 310. The plunger head 380 may be sized to tightly fit within the second infusion body 310 for forcing the second substance 50 out of the second infusion body 310 through the second nozzle 320.
Accordingly, the components of the first and second infusion devices 10, 20 may cooperate to form the infusion assembly 100 as a single device capable of sequential delivery, with the advantage of being separately usable for administering the first and second substances 25, 50 individually, if desired. By providing components that may be used separately or in combination, sterilization of the first and second substances 25, 50 can be achieved independently, without special procedures or extensive steps for sterilizing two separate substances stored in a single device. For example, the application of the infusion assembly 100 for treating bovine mastitis requires sterilization of the antibacterial substance and the teat sealant substance. The sterilization of these two substances requires disparate gamma radiation parameters, as previously described. As such, the individual and combinable aspects of the present disclosure allow for the storage, sterilization, and distribution of the two substances separately, but with the advantage of combining the components into a single device.
In use, as shown in
Alternatively, in some instances, the infusion assembly 100 may be configured such that the first plunger 130 (comprised of both the translating member 150 and the stopper piston 200) is removed from the first infusion device 10 so that the first plunger 130 is separated from the first infusion body 110. Once the first plunger 130 is removed, the stopper piston 200 may then be separated from the translating member 150. Then, the stopper piston 200 may be positioned on the second nozzle 320 of the second infusion device 20.
In any instance, the second nozzle 320 may be received within the cavity 210 of the stopper piston 200. The stopper piston 200 may be positioned against the first substance 25 contained within the first infusion body 110. The second infusion body 310 may be positioned within the first infusion body 110. In this regard, in the case of being tubular shaped, the diameter of the second infusion body 310 is less than the diameter of the first infusion body 110 such that the second infusion body 310 may be received therewithin. In this manner, a single assembly device may be formed for sequentially delivering the first and second substances 25, 50 to a target site using only a single insertion event.
With the first infusion device 10 and second infusion device 20 combined to form the infusion assembly 100, the second plunger 330 may be plunged or otherwise advanced to expel the first substance 25 from the first infusion body 110 through the first nozzle 120. In this regard, the stopper piston 200 may be forced toward the first nozzle 120 during plunging of the second plunger 330 to interact with the first substance 25, thereby forcing the first substance 25 out of the first infusion body 110. Alternatively, the second flange 370 may be advanced rather than the second plunger 330 for dispensing the first substance 25 from the first infusion body 110, as such movement will also advance the second plunger 330 toward the first nozzle 120.
After dispensing the first substance 25, the second plunger 330 may be plunged or otherwise advanced to expel the second substance 50 from the second infusion body 310 through the second nozzle 320, and then through the first nozzle 120 into the target site. The second nozzle 320 may be configured to mate within the first nozzle 120 when the second plunger 330 is in a fully plunged or fully advanced position in which the second plunger 330 cannot be advanced any further. In some instances, the second nozzle 320 may be configured to fully extend through and out of the stopper piston 200. Once the second plunger 330 is in the fully advanced position, the first and second substances 25, 50 have been sequentially delivered to the target site using only a single insertion event.
In some instances, the viscosity of the first and second substances 25, 50 may affect the operation of the device. For example, in the case of treating bovine mastitis, the teat sealant product (paste-like) may have a substantially higher viscosity than the antimicrobial product (water-like). In such instances, initially advancing the second plunger 330 forces the first substance 25 (e.g., the antimicrobial substance) out of the first nozzle 120 rather than forcing the second substance 50 (e.g., the teat sealant substance) out of the second nozzle 320 to undesirably mix with the first substance 25. Of course, in some instances, this may be avoided by sealing the end of the stopper piston 200, as discussed further below.
According to some aspects of the present disclosure, the stopper piston 200 may be sealed, non-sealed, or semi-sealed, as used to describe the requirement of the second nozzle 320 to deliver the second substance 50 to the first nozzle 120 for evacuation thereof from the infusion assembly 100. In some instances, as shown in
In other instances, as shown in
According to other aspects, as shown in
In accordance with some aspects of the present disclosure, as shown in
In some instances, the compressible stopper piston 200 may include one or more structural ribs 260, each extending between the stopper base 270 and the stopper head 280 in a non-perpendicular manner. That is, the structural ribs 260 may be configured to extend angularly or in a serpentine manner between the stopper base 270 and the stopper head 280. The compressible stopper piston 200 may include cut-away portions that allow for collapsing thereof. The compressible stopper piston 200 may be made of an appropriate pliant material that permits compressing thereof. In some instances, the stopper head 280 may be dome-shaped or substantially frustoconical. The stopper head 280 may extend radially outward to circumferentially encase the first chamber 165.
According to other aspects of the present disclosure, the stopper piston 200 may be substantially non-compressible in that the stopper piston 200 is not compressed when pierced by the second nozzle 320; however, the stopper piston 200 in such instances may be resiliently-formed. In such aspects, the infusion assembly 100 may function to sequentially deliver multiple substances based on a two-stage or two-phase seating configuration or arrangement of the second nozzle 320 with respect to the stopper piston 200, as shown in
In the first seating position, as shown in
When the stopper piston 200 advances completely within the first infusion body 110 (i.e., the stopper head 280 meets and contacts an end wall 115 of the first infusion body 110), further advancement of the second plunger 330 may cause the second infusion body 310 to advance such that the second nozzle 320 moves into the second seating position, as shown in
The stopper piston 200 may define the cavity 210 so as to appropriately create the first and second seating positions for the second nozzle 320. According to one aspect, as shown in
Upon moving to the second seating position within the stopper piston 200, the second nozzle 320 advances within the cavity 210 so as to pierce or penetrate the penetrable portion 220 or slit 250. The second nozzle 320 may advance so as to become nested within the first nozzle 120. In the second seating position, the flange 322 and/or other components of the second nozzle 320 or second infusion body 310 may be seated or otherwise received within a second recess 214 defined by the stopper piston 200, wherein the flange 322 may abut a second abutment section 255. According to some aspects, the second recess 214 may be correspondingly defined to receive a portion of the second nozzle 320. For example, the stopper piston 200 may define an annular recess 216 for receiving the flange 322 when the second nozzle 320 is positioned in the second seating position. Additionally, the stopper piston may define a tapered recess section for receiving a correspondingly tapered section 318 of the second nozzle 320.
In some instances, a collar 312 or shoulder 314 of the second infusion body 310 may interact with internal sections of the stopper piston 200 or a back end 240 of the stopper piston 200 to form a stop such that the second nozzle 320 cannot advance any further. The back end 240 may be appropriately configured or shaped to provide sufficient clearance between the back end 240 and the collar 312 or shoulder 314 to allow enough movement by the second nozzle 320 to pierce the penetrable portion 220 or slit 250.
The stopper piston 200 may further include or otherwise define a resistance member 225, such as, for example, an integrally-formed O-ring, which resistively interacts and contacts the second nozzle 320 such that the second nozzle 320 and the second infusion body 310 remain securely engaged or intact with the stopper piston 200 once coupled. The resistance member 225 may act as an additional resistance point that allows the second nozzle 320 to advance the stopper piston 200.
Many modifications and other aspects of the present disclosure set forth herein will come to mind to one skilled in the art to which this disclosure pertains having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the present disclosure is not to be limited to the specific aspects disclosed and that modifications and other aspects are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
This application claims the benefit of U.S. Provisional Patent Application Nos. 61/878,162, filed Sep. 16, 2013, and 62/026,936, filed Jul. 21, 2014, both of which are expressly incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2159217 | Lozier et al. | May 1939 | A |
2193322 | Lozier et al. | Mar 1940 | A |
2687728 | Copen | Aug 1954 | A |
2939459 | Lazarte et al. | Jun 1960 | A |
3346147 | Higgins et al. | Oct 1967 | A |
3563240 | Silver | Feb 1971 | A |
3749084 | Cucchiara | Jul 1973 | A |
3766917 | Wimmer | Oct 1973 | A |
3911916 | Stevens | Oct 1975 | A |
3923058 | Weingarten | Dec 1975 | A |
3986645 | Baldwin et al. | Oct 1976 | A |
4188949 | Antoshkiw | Feb 1980 | A |
4313440 | Ashley | Feb 1982 | A |
4394863 | Bartner | Jul 1983 | A |
4439184 | Wheeler | Mar 1984 | A |
4702737 | Pizzino | Oct 1987 | A |
5026346 | Spanner et al. | Jun 1991 | A |
5102388 | Richmond | Apr 1992 | A |
5279606 | Haber et al. | Jan 1994 | A |
5298024 | Richmond | Mar 1994 | A |
5415648 | Malay et al. | May 1995 | A |
5476449 | Richmond | Dec 1995 | A |
5520657 | Sellers et al. | May 1996 | A |
5704918 | Higashikawa | Jan 1998 | A |
5720731 | Aramata et al. | Feb 1998 | A |
6077252 | Siegel | Jun 2000 | A |
6149628 | Szapiro et al. | Nov 2000 | A |
6440101 | Grabenkort et al. | Aug 2002 | B1 |
6458095 | Wirt et al. | Oct 2002 | B1 |
6558358 | Rosoff et al. | May 2003 | B2 |
6723074 | Halseth | Apr 2004 | B1 |
6802822 | Dodge | Oct 2004 | B1 |
6866653 | Bae | Mar 2005 | B2 |
7011650 | Rosoff et al. | Mar 2006 | B2 |
7828765 | Hallahan et al. | Nov 2010 | B2 |
8353877 | Hallahan et al. | Jan 2013 | B2 |
20020068910 | Szapiro et al. | Jun 2002 | A1 |
20020198490 | Wirt et al. | Dec 2002 | A1 |
20030060414 | McHardy et al. | Mar 2003 | A1 |
20030236503 | Koenig et al. | Dec 2003 | A1 |
20040044316 | Greenfield | Mar 2004 | A1 |
20040116871 | Vincent | Jun 2004 | A1 |
20050245880 | Howlett et al. | Nov 2005 | A1 |
20060052747 | Nishimura et al. | Mar 2006 | A1 |
20070264310 | Hissong | Nov 2007 | A1 |
20080208137 | Fago | Aug 2008 | A1 |
20100286513 | Pollard, Jr. | Nov 2010 | A1 |
20110160674 | Holmes et al. | Jun 2011 | A1 |
20120323173 | Thorne, Jr. | Dec 2012 | A1 |
20140276630 | Pokorney et al. | Sep 2014 | A1 |
Number | Date | Country |
---|---|---|
2543299 | May 2005 | CA |
202605441 | Dec 2012 | CN |
2514201 | Oct 1976 | DE |
10110126 | Sep 2002 | DE |
0082251 | Sep 1982 | EP |
0078899 | May 1983 | EP |
0737484 | Oct 1996 | EP |
2620124 | Jul 2013 | EP |
2076853 | Oct 1971 | FR |
2251339 | Jun 1975 | FR |
2506161 | Nov 1982 | FR |
2573310 | May 1986 | FR |
2750051 | Dec 1997 | FR |
1441747 | Jul 1976 | GB |
2376048 | Dec 2002 | GB |
58-133260 | Aug 1983 | JP |
8294532 | Nov 1996 | JP |
2003-299734 | Oct 2003 | JP |
WO 9116094 | Oct 1991 | WO |
WO 9413261 | Jun 1994 | WO |
WO 9531180 | Nov 1995 | WO |
WO 9826759 | Jun 1998 | WO |
WO 9917820 | Apr 1999 | WO |
WO 0211793 | Feb 2002 | WO |
WO 02072171 | Sep 2002 | WO |
WO 2004039434 | May 2004 | WO |
WO 2005072644 | Aug 2005 | WO |
WO 2007006030 | Jan 2007 | WO |
WO 2009094345 | Jul 2009 | WO |
WO 2013021186 | Feb 2013 | WO |
WO 2014001353 | Jan 2014 | WO |
Entry |
---|
International Search Report and Written Opinion, International Application No. PCT/US2014/051194, date of mailing Oct. 23, 2014. |
Canadian Office Action, Canadian Patent Application No. 2,923,555. |
Number | Date | Country | |
---|---|---|---|
20150080841 A1 | Mar 2015 | US |
Number | Date | Country | |
---|---|---|---|
62026936 | Jul 2014 | US | |
61878162 | Sep 2013 | US |